We examined neuroendocrine markers, including CD56, SYP, and CgA, in 36 ameloblastomas and identified five specimens that exhibited the immunoexpression of CD56 and SYP, suggesting neuroendocrine differentiation in ameloblastomas. The gene discussed is CGA; the disease is ameloblastoma.